ROCK HILL, S.C. - 3D Systems (NYSE:DDD) has garnered a significant milestone with the Food and Drug Administration's (FDA) 510(k) clearance for its VSP PEEK Cranial Implant, a 3D-printed, patient-specific implant for cranial reconstruction. This clearance paves the way for broader use of the company's additive manufacturing solutions in the United States.
The VSP PEEK Cranial Implant system includes 3D Systems' EXT 220 MED 3D printer and Evonik VESTAKEEP i4 3DF PEEK material, which is designed to produce implants with substantially less material than traditional methods. The self-contained, cleanroom environment-based printing system has already been utilized in nearly 40 successful cranioplasties across Europe, demonstrating its potential for cost-effective and precise patient care.
The implants are made from medical-grade PEEK, a high-performance polymer known for its mechanical properties that closely resemble human bone, biocompatibility, and stability. Its radiolucency is also beneficial as it minimizes interference with medical imaging.
Dr. Johannes Pöppe, a senior attending surgeon at University Hospital Salzburg, noted the transformative impact of 3D-printed PEEK cranial plates in neurosurgery, highlighting their role in integrating 3D printing into routine clinical practice.
The market for cranial reconstruction is expected to grow, with projections reaching $2.1 billion by 2030. 3D Systems' FDA clearance is seen as a foundation for the company to expand its PEEK product portfolio and explore additional orthopedic applications.
3D Systems has a history of collaboration with surgeons, planning over 150,000 patient-specific cases and producing more than two million implants and instruments. The company's expertise and FDA-registered, ISO 13485-certified facilities are positioned to accelerate the development process for partners and customers, ensuring quicker access to the market for new medical solutions.
The FDA clearance is based on a press release statement from 3D Systems.
InvestingPro Insights
As 3D Systems (NYSE:DDD) achieves a new milestone with the FDA's clearance for its VSP PEEK Cranial Implant, the company's financial health and market performance provide additional context for investors. According to real-time data from InvestingPro, 3D Systems currently has a market capitalization of $494.39 million. Despite a challenging revenue growth trajectory with a -9.29% change over the last twelve months as of Q4 2023, the company maintains a gross profit margin of 40.73%, indicating a strong ability to convert sales into profit.
The recent performance metrics show that 3D Systems' stock price has been quite volatile, trading near its 52-week low. This is significant as the company's shares have fallen by -56.78% over the last year, potentially presenting a buying opportunity for investors who believe in the company's long-term strategy and FDA clearance as a driver for future growth.
InvestingPro Tips highlight two key points for potential investors: 3D Systems has a high shareholder yield and its net income is expected to grow this year. These factors could be indicative of a company that is poised for a turnaround, especially when considering strategic advancements like the recent FDA approval. However, it's important to note that analysts do not anticipate the company will be profitable this year, and the stock has been marked by five analyst downgrades for the upcoming period.
For those interested in a deeper analysis, InvestingPro offers additional tips on 3D Systems, which can be accessed at https://www.investing.com/pro/DDD. To enrich your investment research, use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription. There are 13 additional InvestingPro Tips available, providing comprehensive insights into the company's financial health and market performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.